This trial is testing a new HIV therapy that uses T-cells from a donor. The trial will study the safety and effectiveness of this new therapy in people who have had a bone marrow transplant.
1 Primary · 2 Secondary · Reporting Duration: 3 years
1 Treatment Group
Donor Derived HIV-Specific T-cells (DD HST-NEETs)
1 of 1
8 Total Participants · 1 Treatment Group
Primary Treatment: DD HST-NEETs · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 27 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are currently receiving treatment in this experiment?
"Affirmative. Data hosted on clinicaltrials.gov verifies that this research venture, which was first created on May 1st 2020, is actively recruiting participants. 8 people need to be sourced from two distinct medical centres." - Anonymous Online Contributor
Has the Drug and Food Administration sanctioned DD HST-NEETs for medical use?
"Our assessment at Power placed DD HST-NEETs on the lower end of safety, with a score of 1. This reflects this protocol's Phase 1 status, which suggests limited data to support both efficacy and security." - Anonymous Online Contributor
Are there any vacancies available for this research project?
"The clinical trial is open for enrollment, as attested to by the records on clinicaltrials.gov from its inception date of May 1st 2020 up until March 2nd 2022." - Anonymous Online Contributor